Low positive yield from routine inclusion of the brain in whole-body 18F-FDG PET/CT imaging for noncerebral malignancies

2013 ◽  
Vol 34 (6) ◽  
pp. 540-543 ◽  
Author(s):  
Kuruva Manohar ◽  
Anish Bhattacharya ◽  
Bhagwant R. Mittal
Keyword(s):  
Fdg Pet ◽  
Ct Imaging ◽  
Whole Body ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
The Brain

scholarly journals Leydig cell tumor of the testis: an incidental finding at 18F-FDG PET/CT imaging

2021 ◽  
Vol 52 (1) ◽  
Author(s):  
Almalki Yassir
Keyword(s):  
Leydig Cell ◽  
Fdg Pet ◽  
Chronic Rejection ◽  
Ct Imaging ◽  
The Body ◽  
Whole Body ◽  
Pet Ct ◽  
18F Fdg ◽  
The Right ◽  
Fdg Pet Ct

Abstract Background Leydig cell tumors (LCTs) represent the most common form of stromal tumors. We reported the 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) findings of a patient with testicular LCT. Case presentation A 50-year-old man with a history of end-stage renal disease and renal transplantation 19 years ago. One year earlier, he started to have a chronic rejection. During the investigation to determine the cause of chronic rejection, a suspicious lesion in the graft with a collection around it was seen on ultrasound (US) images, raising the possibility of post-transplant lymphoproliferative disorder (PTLD). The patient was referred for further evaluation by whole body 18F-FDG PET/CT imaging. The image finding revealed an incidental hypermetabolic focal lesion in the right testicle—no other specific findings in the remaining parts of the body nor definitive FDG avid lymphadenopathy to suggest PTLD. Testicular US was requested and showed a well-defined right-sided heterogeneous hypoechoic intratesticular focal mass at the upper pole of the right testis with significant internal vascularity on the color Doppler imaging. The patient underwent a right radical orchidectomy, and the tumor was pathologically confirmed as an LCT. Conclusion In our case, 18F-FDG-PET/CT has been helpful in incidentally detecting this rare testicular tumor in a patient with suspected PTLD.

scholarly journals An unusual case of pituitary pathology and the utility of whole body 18F-FDG PET-CT imaging in identifying extraneural biopsy targets

2015 ◽  
Author(s):  
Jenna Deakin ◽  
Michelle Siu ◽  
Harriet Cunningham ◽  
Nikhil Patel ◽  
Thomas Osborne ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Unusual Case ◽  
Ct Imaging ◽  
Whole Body ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

scholarly journals Brain Metastases Unresponsive to Immunotherapy Detected by 18F-FDG-PET/CT in a Patient with Melanoma

Diagnostics ◽  
2020 ◽  
Vol 10 (6) ◽  
pp. 410 ◽  
Author(s):  
Rosa Fonti ◽  
Sara Pellegrino ◽  
Ciro Gabriele Mainolfi ◽  
Elide Matano ◽  
Silvana Del Vecchio
Keyword(s):  
Monoclonal Antibody ◽  
Brain Metastases ◽  
Fdg Pet ◽  
Palliative Therapy ◽  
Advanced Melanoma ◽  
Whole Body ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
The Brain

Recently, newer therapies such as immunotherapy have been increasingly used in the treatment of several tumors, including advanced melanoma. In particular, several studies showed that the combination of ipilimumab, an anti-Cytotoxic T-lymphocyte Associated Protein 4 (CTLA-4) monoclonal antibody and nivolumab, an anti-Programmed Death 1 (PD-1) monoclonal antibody, leads to improved survival in patients with metastatic melanoma. Despite that, immunotherapeutic agents may not reach therapeutic concentration in the brain due to the blood–brain barrier. We report the case of a 50-year-old man with advanced melanoma who underwent whole-body 18F-FDG-PET/CT before and after treatment with immunotherapy showing resistant brain metastases confirmed by subsequent MRI of the brain. Moreover, 18F-FDG-PET/CT was able to detect an immune-related adverse event such as enterocolitis that contributed to the worsening of patient conditions. This case shows how a whole-body methodology such as 18F-FDG-PET/CT can be useful in identifying melanoma cancer patients unresponsive to immunotherapy that may benefit from traditional palliative therapy in the effort to improve their quality of life.

The value of whole-body contrast-enhanced 18F-FDG PET/CT imaging in the diagnosis and staging of patients with laryngeal carcinoma

2018 ◽  
Vol 39 (4) ◽  
pp. 334-342 ◽  
Author(s):  
Gamze Tatar ◽  
Tevfik F. Cermik ◽  
Yesim Karagoz ◽  
Cihan Gundogan ◽  
Didem Karacetin ◽  
...  
Keyword(s):  
Laryngeal Carcinoma ◽  
Fdg Pet ◽  
Ct Imaging ◽  
Whole Body ◽  
Contrast Enhanced ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

scholarly journals 18F-FDG PET/CT imaging findings of multiple solitary fibrous tumor

Medicine ◽  
2019 ◽  
Vol 98 (32) ◽  
pp. e16743
Author(s):  
Xiaofei Liu ◽  
Wenhua Zhu ◽  
Xiaohong Zhou ◽  
Hao Yao ◽  
Jiagui Su ◽  
...  
Keyword(s):  
Solitary Fibrous Tumor ◽  
Fdg Pet ◽  
Ct Imaging ◽  
Imaging Findings ◽  
Pet Ct ◽  
18F Fdg ◽  
Fibrous Tumor ◽  
Fdg Pet Ct

scholarly journals Hibernoma: 18F FDG PET/CT Imaging

2007 ◽  
Vol 2 (6) ◽  
pp. 569-570 ◽  
Author(s):  
Rathan M. Subramaniam ◽  
Amy C. Clayton ◽  
Dimitrios Karantanis ◽  
Douglas A. Collins
Keyword(s):  
Fdg Pet ◽  
Ct Imaging ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

scholarly journals 18F-FDG PET/CT Imaging In Oncology

2011 ◽  
Vol 31 (1) ◽  
pp. 3-13 ◽  
Author(s):  
Ahmad Almuhaideb ◽  
Nikolaos Papathanasiou ◽  
Jamshed Bomanji
Keyword(s):  
Fdg Pet ◽  
Ct Imaging ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

scholarly journals Comparison of the diagnostic performance and impact on management of 18F-FDG PET/CT and whole-body MRI in multiple myeloma

2021 ◽  
Author(s):  
Olwen Westerland ◽  
◽  
Ashik Amlani ◽  
Christian Kelly-Morland ◽  
Michal Fraczek ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Clinical Data ◽  
Bone Disease ◽  
Fdg Pet ◽  
Diagnostic Performance ◽  
Whole Body ◽  
Bone Lesions ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Abstract Purpose Comparative data on the impact of imaging on management is lacking for multiple myeloma. This study compared the diagnostic performance and impact on management of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and whole-body magnetic resonance imaging (WBMRI) in treatment-naive myeloma. Methods Forty-six patients undergoing 18F-FDG PET/CT and WBMRI were reviewed by a nuclear medicine physician and radiologist, respectively, for the presence of myeloma bone disease. Blinded clinical and imaging data were reviewed by two haematologists in consensus and management recorded following clinical data ± 18F-FDG PET/CT or WBMRI. Bone disease was defined using International Myeloma Working Group (IMWG) criteria and a clinical reference standard. Per-patient sensitivity for lesion detection was established. McNemar test compared management based on clinical assessment ± 18F-FDG PET/CT or WBMRI. Results Sensitivity for bone lesions was 69.6% (32/46) for 18F-FDG PET/CT (54.3% (25/46) for PET component alone) and 91.3% (42/46) for WBMRI. 27/46 (58.7%) of cases were concordant. In 19/46 patients (41.3%) WBMRI detected more focal bone lesions than 18F-FDG PET/CT. Based on clinical data alone, 32/46 (69.6%) patients would have been treated. Addition of 18F-FDG PET/CT to clinical data increased this to 40/46 (87.0%) patients (p = 0.02); and WBMRI to clinical data to 43/46 (93.5%) patients (p = 0.002). The difference in treatment decisions was not statistically significant between 18F-FDG PET/CT and WBMRI (p = 0.08). Conclusion Compared to 18F-FDG PET/CT, WBMRI had a higher per patient sensitivity for bone disease. However, treatment decisions were not statistically different and either modality would be appropriate in initial staging, depending on local availability and expertise.

Sign in / Sign up

Export Citation Format

Share Document